SeaStar Medical reports survival benefits for pediatric sepsis device

SeaStar Medical reported positive survival findings for its novel QUELIMMUNE device in children suffering from sepsis-associated acute kidney injury on October 22, 2026. According to reports by The Manila Times, GlobeNewswire, and StreetInsider, the new data was presented at ASN Kidney Week 2026. [1][2][3]

The Manila Times reported that the primary analysis of the post-approval SAVE Registry demonstrated statistically significant higher survival rates for the treatment group at Day 60, Day 90, and at hospital discharge compared to a control cohort. The therapy experienced no device-related adverse events during the trial period. [1]

Sepsis is a life-threatening medical condition that develops when the human body has a dysregulated response to an infection, causing injury to its own tissues and internal organs. [6]